2025年,在中国未盈利创新药企开启上市融资7年后,创新药迎来了久违的股市回暖。自2018年8月歌礼制药-B(01672.HK)成为“18A第一股”以来,已有70家创新药企(74支股)在港股18A或科创板上市。在这个中报季,它们都交出了怎样的答卷?据经济观察报统计,2025年上半年,已有15家企业实现盈利,其中6家企业属于首度扭亏为盈,包括百济神州(ONC.NASDAQ/06160.HK/...
Source Link2025年,在中国未盈利创新药企开启上市融资7年后,创新药迎来了久违的股市回暖。自2018年8月歌礼制药-B(01672.HK)成为“18A第一股”以来,已有70家创新药企(74支股)在港股18A或科创板上市。在这个中报季,它们都交出了怎样的答卷?据经济观察报统计,2025年上半年,已有15家企业实现盈利,其中6家企业属于首度扭亏为盈,包括百济神州(ONC.NASDAQ/06160.HK/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.